PRA Health Sciences delivers innovative drug development solutions that improve patients’ lives. Our people are passionate about clinical research, working tirelessly to provide quality results. We offer exceptional experience across all phases and therapeutic areas and a broad spectrum of solutions, ranging from full-service clinical development to a pioneering embedded model.
With 16,000+ employees covering 90+ countries, we bolster an impressive global presence with keen local insights. Our project teams harness their understanding of local regulations, standards of care and cultural customs to effectively align our approaches with each study’s unique goals.
At PRA, we love what do because we are making a difference in the lives of patients and their family members worldwide. Over the years, we have contributed to the development of numerous drugs now available to countless patients. From our scientific and medical experts to therapeutically aligned project managers and monitors, we provide the commitment and expertise needed for today’s complex studies.
PSR and Ergomed joined forces to create the leading orphan drug development team, allowing our clients to implement patient-driven solutions in their clinical trials. Our orphan disease toolkit reflects a genuine family and patient approach to recruitment and retention.
Comradis was established to tackle the communication challenges of rare diseases. The heterogeneity of rare diseases means that there is no silver bullet to addressing them all. We work with pharmaceutical companies, rare disease specialists and patient advocacy organizations to understand the challenges that are unique to each situation and to push the boundaries of medical communications to address them.
Comradis is part of AMICULUM®, an independent global healthcare communications and learning business.
Clinigen exists to make sure healthcare professionals with a patient in need, anywhere in the world, can always get the right medicine for their individual patient – quickly, easily, and safely whether licensed or unlicensed.
Population growth, an increasingly elderly population, growing incidences of chronic diseases and rare or orphan medicines, increasing patient knowledge, and concerns around counterfeit medicines are all driving increasing demand for quality medicines that are not available at the ‘point of care’.
RareLife solutions offers novel technology and critical thinking to modernize the successful development and commercialization of products for rare diseases. Our offerings cut across all phases of product development to bring efficiencies and intelligence that help companies progress drugs for rare diseases smarter and more efficiently. Our fundamental belief that influences our offerings is built on the insight that rare patients, advocates, and caregivers (PACs) are the primary shapers of their rare disease ecosystem so meaningfully partnering with them is critical to success.
